Evidence map›Paper›PMID 42008658›Full record

Trial reportAntimicrobial agents and chemotherapy2026

Evaluation of the cytochrome P450-mediated drug interaction profile of olorofim.

Karen Cornelissen, John H Rex, Daniela Zinzi, Derek Law, Rachel Upcott Gill, Hannah M Jones, Johan Maertens, Sharon C-A Chen, Roger Brüggemann

Abstract readClinical Trial, Phase IClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Karen CornelissenF2G Ltd, Nether Alderley, Macclesfield, United Kingdom.ORCID 0009-0004-4338-4988
John H RexF2G Ltd, Nether Alderley, Macclesfield, United Kingdom.
Daniela ZinziF2G Ltd, Nether Alderley, Macclesfield, United Kingdom.
Derek LawF2G Ltd, Nether Alderley, Macclesfield, United Kingdom.
Rachel Upcott GillCyprotex Discovery Ltd, Macclesfield, United Kingdom.
Hannah M JonesCertara UK Ltd, Sheffield, United Kingdom.
Johan MaertensDepartment of Hematology, University Hospitals Leuven, Leuven, Belgium.
Sharon C-A ChenCentre for Infectious Diseases and Microbiology Laboratory Services, Department of Infectious Diseases, Institute for Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The University of Sydney, Sydney, Australia.
Roger BrüggemannRadboud University Medical Centre, Nijmegen, the Netherlands.ORCID 0000-0002-7618-725X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Olorofim is a novel oral antifungal agent which selectively inhibits the fungal enzyme dihydroorotate dehydrogenase found in molds including

Indexed as

Antifungal AgentsCytochrome P-450 Enzyme SystemPiperazinesPyrimidinesAcetamidesBiphenyl CompoundsCytochrome P-450 CYP1A2Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsDrug InteractionsFluconazoleHumansAcetamidesAntifungal AgentsBiphenyl CompoundsCYP1A2 protein, humanCYP2B6 protein, humanCYP2C8 protein, humanCYP2C9 protein, humanCYP3A4 protein, humanCytochrome P-450 CYP1A2Cytochrome P-450 CYP2B6Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2C9Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InhibitorsCytochrome P-450 Enzyme SystemFluconazoleolorofimPiperazinesPyrimidinesPyrrolesdrug interactionolorofim

Identifiers

PMID42008658
PMCPMC13231911

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.